Business Context and Reporting Period
This Form 8-K is filed by AmerisourceBergen Corporation (now Cencora, Inc.) on January 23, 2020, reporting events occurring on January 23 and January 30, 2020. The filing primarily addresses the announcement of fiscal quarter results ended December 31, 2019, and a strategic decision by the Board of Directors to exit the PharMEDium compounding business.
Key Financial Metrics and Material Changes
PharMEDium Exit and Impairments
- Prior Impairment: A $138.0 million impairment charge was recognized in the three months ended December 31, 2019.
- Expected Future Impairments: The Company expects to impair the majority of the remaining $55 million in tangible assets and all $185 million in intangible assets in the quarter ending March 31, 2020.
- Exit Costs: Estimated employee separation and other costs to exit the business during fiscal year 2020 are projected at $80 million to $100 million.
- Tax Impact: The Company anticipates an ordinary income tax deduction resulting in a cash tax benefit of approximately $500 million to $600 million realized between fiscal 2020 and fiscal 2022.
Operational Context
The decision to cease commercial and administrative operations for PharMEDium was driven by operational, regulatory, and commercial challenges, including a January 2020 suspension of production at the New Jersey facility pending air handling and filtration upgrades.
Guidance, Outlook, and Risks
The filing incorporates forward-looking statements regarding the exit strategy and financial impacts. Management does not provide specific revenue or earnings guidance for the full fiscal year within this document, referring investors to the news release (Exhibit 99.1) and conference call for detailed results.
Material Risks and Contingencies
- Regulatory and Legal: Risks include ongoing opioid litigation, government enforcement regarding controlled substances, and compliance with the Corporate Integrity Agreement.
- Operational: Challenges related to pharmaceutical pricing, reimbursement rates, and supply chain disruptions.
- Strategic: Risks associated with the relationship with Walgreens Boots Alliance and the integration or divestiture of business units.
Investor Verification Checklist
- Verify the total expected impairment charges ($138M prior + ~$240M future) and their impact on Q1 2020 earnings.
- Confirm the timeline and realization of the estimated $500M-$600M cash tax benefit.
- Review the attached news release (Exhibit 99.1) for specific Q4 2019 revenue and net income figures not detailed in the 8-K text.
- Monitor the status of the New Jersey facility upgrades and the timeline for the complete cessation of PharMEDium operations.
- Assess the impact of the exit on the Company's overall liquidity and debt covenants.